Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Hepatitis C infection: Therapeutic strategies].
Diatta T, Chavade D, Degos F, d'Andon A, Guillevin L. Diatta T, et al. Among authors: degos f. Presse Med. 2016 May;45(5):495-508. doi: 10.1016/j.lpm.2016.02.006. Epub 2016 Mar 19. Presse Med. 2016. PMID: 27006245 Review. French.
Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial.
Fartoux L, Degos F, Trépo C, Goria O, Calès P, Tran A, Buffet C, Poynard T, Capron D, Raabe JJ, Roulot D, Naveau S, Grange JD, Poupon RE, Poupon R, Serfaty L. Fartoux L, et al. Among authors: degos f. Clin Gastroenterol Hepatol. 2007 Apr;5(4):502-7. doi: 10.1016/j.cgh.2006.10.016. Epub 2007 Jan 29. Clin Gastroenterol Hepatol. 2007. PMID: 17261383 Clinical Trial.
[Vaccination against hepatitis B virus].
Degos F. Degos F. Presse Med. 2006 Feb;35(2 Pt 2):347-52. doi: 10.1016/s0755-4982(06)74580-8. Presse Med. 2006. PMID: 16493339 Review. French.
[Cytokines and hepatitis].
Degos F. Degos F. Rev Prat. 1993 Mar 1;43(5):569-73. Rev Prat. 1993. PMID: 7688135 French.
Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial.
Poynard T, Marcellin P, Bissery A, Myers RP, Moussalli J, Degos F, Dhumeaux D, Riachi G, Bronowicki JP, Brissot P, Buffet C, Serfaty L, Naveau S, Sogni P, Beaugrand M, Gayno S, Larrey D, Samuel D, Eugene C, Pol S, Bedossa P, Daurat V, Chaumet-Riffaud P; GER-CYT-RIBANON group. Poynard T, et al. Among authors: degos f. J Viral Hepat. 2003 May;10(3):197-204. doi: 10.1046/j.1365-2893.2003.00427.x. J Viral Hepat. 2003. PMID: 12753338 Clinical Trial.
Reinforced regimen of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: a multicentre randomised trial. Multicentre GER-CYT-04 Group.
Degos F, Daurat V, Chevret S, Gayno S, Bastie A, Riachi G, Bartolomei-Portal I, Barange K, Moussalli J, Naveau S, Bailly F, Chaumet-Riffaud P, Chastang C. Degos F, et al. J Hepatol. 1998 Aug;29(2):224-32. doi: 10.1016/s0168-8278(98)80007-x. J Hepatol. 1998. PMID: 9722203 Clinical Trial.
Prognostic value of the soluble interleukin-2 receptor in chronic hepatitis C treated with interferon-alfa. Multicenter GER-CYT 04 Group.
Naveau S, Balian A, Degos F, Daurat V, Chevret S, Gayno S, Bastie A, Riachi G, Bartolomei-Portal I, Barange K, Moussalli J, Bailly F, Chaumet-Riffaud P, Emilie D. Naveau S, et al. Among authors: degos f. J Hepatol. 1999 Oct;31(4):612-7. doi: 10.1016/s0168-8278(99)80339-0. J Hepatol. 1999. PMID: 10551383 Clinical Trial.
Re-treatment with interferon alfa of patients with chronic hepatitis C.
Chow WC, Boyer N, Pouteau M, Castelnau C, Martinot-Peignoux M, Martins-Amado V, Degos F, Maghinici C, Sinegre M, Benhamou JP, Degott C, Erlinger S, Marcellin P. Chow WC, et al. Among authors: degos f. Hepatology. 1998 Apr;27(4):1144-8. doi: 10.1002/hep.510270432. Hepatology. 1998. PMID: 9537456
173 results